The FDA, Unicure, and the Limits of Accelerated Approval
The Doctors’ Lounge · May 25, 2026 · 53:08
The Doctors’ Lounge · May 25, 2026 · 53:08
Listen in the Podli app 🎧
Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.
Episode Summary
Anish sits down with Adu, a med student and biotech investor, to work through the FDA's contested handling of Unicure's AMT-130 — a gene therapy for Huntington's disease delivered via stereotactic brain injection. They debate whether the underlying data justifies approval, why the agency's mid-course reversal has rattled the investor community, and what the Sarepta precedent should have taught everyone involved. The conversation broadens into a bigger question: given that desperate patient populations will always demand access to anything showing a signal, who is actually best positioned to make the call on whether a drug works — the FDA, the clinician, or the market?
Chapter Markers
00:00 FDA approval of AMT-130 and investor reaction
01:16 Unmet need and the case for regulatory flexibility
02:37 Sarepta, Duchenne's, and the cost of approving under pressure
05:09 Accelerated approval done right: the Amylyx example
09:14 Debating the AMT-130 data and the historical control problem
13:53 Why stock price matters for trial funding
17:20 How Prasad could have changed FDA culture differently
19:37 The FDA's role from Kefauver-Harris to today
22:26 Competing Huntington's therapies in the pipeline
25:39 Prasad's tenure: what worked, what didn't
28:27 Media coverage of the FDA and science journalism
Co-Host Handles
@anish_koka and @drdigiorgio
Show Handle
@drsloungepod
🔗 Connect with the Hosts:
